SightfileU.S. market data from official filings

Companies › ALLO

ALLOGENE THERAPEUTICS INC (ALLO)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001737287 · EDGAR filings · Updated 2026-07-06

ALLOGENE THERAPEUTICS INC (ALLO) has reported institutional ownership of 75.5%, with 208 institutional managers holding positions valued at $444.7M per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02).

Institutional ownership
75.5%
Institutional managers
208
Reported 13F value
$444.7M
Insider activity
15 trans.
−$640.1K net selling
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ALLOGENE THERAPEUTICS INC has 208 institutional holders and institutional ownership of 75.5%.

Insider activity

Insiders reported 15 transactions (0 buys, 14 sells) across 9 reporting insiders, with a net reported value of −$640.1K.

Data flags from SEC filings

Active non-reliance notice on previously issued financial statements (8-K Item 4.02), most recently filed 2024-02-16 (recurring since 2024-02-16) — source filing. The authoritative details are those stated in the filing itself.

Related companies

LEXEO THERAPEUTICS INC (LXEO) · INMODE LTD (INMD) · MIMEDX GROUP INC (MDXG) · MANNKIND CORP (MNKD) · ETON PHARMACEUTICALS INC (ETON) · ANGIODYNAMICS INC (ANGO)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-06.